Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device

Evaluation of pharmacokinetics, user handling, and tolerability of peginterferon alfa-2a (40 kDa) delivered via a disposable autoinjector device

Peter Varunok1, Eric Lawitz2, Kimberly L Beavers3, Gary Matusow4, Ruby Leong5, Nathalie Lambert6, Coen Bernaards7, Jonathan Solsky5, Barbara J Brennan5, Cynthia Wat8, Anne Bertasso51Gastroenterology Associates, Poughkeepsie, NY, USA; 2Alamo Medical Research, San Antonio, TX, USA; 3Asheville Gastroen...

Full description

Bibliographic Details
Main Authors:	Varunok P, Lawitz E, Beavers KL, Matusow G, Leong R, Lambert N, Bernaards C, Solsky J, Brennan BJ, Wat C, Bertasso A
Format:	Article
Language:	English
Published:	Dove Medical Press 2011-11-01
Series:	Patient Preference and Adherence
Online Access:	http://www.dovepress.com/evaluation-of-pharmacokinetics-user-handling-and-tolerability-of-pegin-a8734

Similar Items

Patient Reported Ease-of-Use with a Disposable Autoinjector in Individuals with Migraine
by: Mead J, et al.
Published: (2020-07-01)

Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers
by: Cecile Berteau, et al.
Published: (2010-09-01)

Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a
by: Rania M. El-Lababidi, et al.
Published: (2020-01-01)

Sustained virological response to treatment of chronic hepatitis C with peginterferon alfa and ribavirin
by: Junior André da Rosa, et al.
Published: (2012-06-01)

The pharmacokinetics of epinephrine/adrenaline autoinjectors
by: Sten Dreborg, et al.
Published: (2021-03-01)

Pressure and Stress Transients in Autoinjector Devices
by: Veilleux, Jean-Christophe
Published: (2019)

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa
by: Liu CH, et al.
Published: (2014-04-01)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
by: Robert Flisiak, et al.
Published: (2016-01-01)

Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population
by: Lange J, et al.
Published: (2015-06-01)

Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia
by: Božić Milena, et al.
Published: (2012-01-01)

Cost effectiveness of peginterferon alfa-2B combined with ribavirin for the treatment of chronic hepatitis C in Brazil
by: Marcelo Cunio Machado Fonseca, et al.

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection
by: Hussien Ahmed, et al.
Published: (2017-03-01)

The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan
by: Wei-Hsin Ko, et al.
Published: (2006)

Combination of Peginterferon α-2b (12 kDa) and Lamivudine in difficult-to-treat chronic hepatitis B-an Indian experience
by: Deepak N. Amarapurkar, et al.
Published: (2005-01-01)

Development of an advanced injection time model for an autoinjector
by: Thueer T, et al.
Published: (2018-06-01)

Adherence with epinephrine autoinjector prescriptions in primary care
by: Elissa M. Abrams, et al.
Published: (2017-11-01)

Adherence to adrenaline autoinjector prescriptions in patients with anaphylaxis
by: Louise Parke, et al.
Published: (2019-11-01)

Comparison of drug delivery with autoinjector versus manual prefilled syringe and between three different autoinjector devices administered in pig thigh
by: Hill RL, et al.
Published: (2016-08-01)

Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B.
by: Patrick Marcellin, et al.
Published: (2020-01-01)

Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
by: Jung-An Lin, et al.
Published: (2014-10-01)

Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C:a retrospective study using the Japanese Interferon Database
by: Sato I, et al.
Published: (2014-12-01)

Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single‐Use Autoinjector: A Phase II Study
by: Jed Kaminetsky, MD, et al.
Published: (2015-12-01)

Autoinjectors Preferred for Intramuscular Epinephrine in Anaphylaxis and Allergic Reactions
by: Ronna L Campbell, et al.
Published: (2016-11-01)

Bioequivalence evaluation of epinephrine autoinjectors with attention to rapid delivery
by: Sclar DA
Published: (2013-04-01)

Are adrenaline autoinjectors fit for purpose? A pilot study of the mechanical and injection performance characteristics of a cartridge- versus a syringe-based autoinjector
by: Andreas Schwirtz, et al.
Published: (2010-11-01)

Early virologic response to сеpeginterferon alfa-2b in combination with ribavirin in treatment of patients with chronic hepatitis C
by: O. O. Znoyko, et al.
Published: (2014-09-01)

Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin.
by: Alex Thompson, et al.
Published: (2014-01-01)

Curación de hepatitis crónica C con 12 semanas de tratamiento con peginterferón-alfa y ribavirina Healing of chronic hepatitis C following 12 week therapy with peginterferon-alpha and ribavirin
by: M. Barreales, et al.
Published: (2007-12-01)

No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
by: Lai Wei, et al.
Published: (2018-01-01)

High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
by: Nae-Yun Heo, et al.
Published: (2013-03-01)

Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience
by: Callis Duffin K, et al.
Published: (2016-10-01)

Virological and immunological predictors of long term outcomes of peginterferon alfa-2a therapy for HBeAg-negative chronic hepatitis B
by: I-Cheng Lee, et al.
Published: (2021-09-01)

Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a
by: Wen Jia, et al.
Published: (2019-05-01)

Peginterferon alfa-2a is associated with elevations in alanine aminotransferase at the end of treatment in chronic hepatitis C patients with sustained virologic response.
by: Chih-Wei Tseng, et al.
Published: (2014-01-01)

Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept Talidomida, peginterferón alfa-2b y ribavirina en el tratamiento de pacientes no respondedores con hepatitis crónica C genotipo 1: estudio piloto
by: Benjamín Pardo-Yules, et al.
Published: (2011-12-01)

Patient satisfaction with the BETACONNECT™ autoinjector for interferon beta-1b
by: Weller I, et al.
Published: (2015-07-01)

Analise da região promotora de um gene de 'alfa'-coixina de 25 KDa
by: Souza Filho, Gonçalo Apolinario de
Published: (1994)

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil
by: Artico Simara, et al.
Published: (2012-12-01)

Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study.
by: Wolf Peter Hofmann, et al.
Published: (2015-01-01)

Improving adrenaline autoinjector adherence: A psychologically informed training for healthcare professionals
by: Béré Mahoney, et al.
Published: (2019-09-01)

Cannot write session to /tmp/vufind_sessions/sess_84prk5sqqgbdn2ivcsbmcvb2dh